Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

[Standards and perspectives in the treatment of lupus nephritis].

Anders HJ.

Dtsch Med Wochenschr. 2013 Aug;138(31-32):1582-4. doi: 10.1055/s-0033-1343258. Epub 2013 Jul 24. Review. German. No abstract available.

PMID:
23884743
2.

Connective tissue diseases: Management of lupus nephritis-new guidelines revealed.

Ginzler E.

Nat Rev Rheumatol. 2012 Oct;8(10):565-6. doi: 10.1038/nrrheum.2012.131. Epub 2012 Jul 31.

PMID:
22847470
3.

Lupus nephritis: Transatlantic management recommendations compared.

Hiepe F.

Nat Rev Rheumatol. 2012 Dec;8(12):697-8. doi: 10.1038/nrrheum.2012.192. Epub 2012 Nov 13. No abstract available.

PMID:
23147901
4.

Overview of lupus nephritis management guidelines and perspective from Asia.

Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR, Sumethkul V, Shen N, Chen SL, Chan TM; Asian Lupus Nephritis Network (ALNN)..

Int J Rheum Dis. 2013 Dec;16(6):625-36. doi: 10.1111/1756-185X.12212. Epub 2013 Oct 31. Review.

PMID:
24382275
5.

[Statement on the use of mycophenolate mofetil for systemic lupus erythematosus].

Aringer M, Fischer-Betz R, Hiepe F; Kommission Pharmakotherapie der DGRh.; Germany Society of Rheumatology..

Z Rheumatol. 2013 Aug;72(6):575-80. doi: 10.1007/s00393-013-1213-y. German.

PMID:
23756593
6.

The NIH pulse cyclophosphamide regime: the end of an era?

Karim Y, D'Cruz DP.

Lupus. 2004;13(1):1-3. No abstract available.

PMID:
14870910
7.

Lupus nephritis: guidelines for lupus nephritis--more recommendations than data?

Rovin BH.

Nat Rev Nephrol. 2012 Nov;8(11):620-1. doi: 10.1038/nrneph.2012.215. Epub 2012 Sep 25. No abstract available.

PMID:
23007619
8.

[Interdisciplinary consensus to management of lupus nephritis in Germany].

de Groot K.

Z Rheumatol. 2007 Dec;66(8):724, 726. German.

PMID:
17965864
9.

How did cyclophosphamide become the drug of choice for lupus nephritis?

Bargman JM.

Nephrol Dial Transplant. 2009 Feb;24(2):381-4. doi: 10.1093/ndt/gfn640. Epub 2008 Dec 4. Review. No abstract available.

PMID:
19056783
10.

Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis.

van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sévaux RG, Berger SP, Derksen RH, Berden JH; Dutch Working Party on Systemic Lupus Erythematosus..

Neth J Med. 2012 May;70(4):199-207. Review.

11.

[Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].

Sixdorf U, Bauer H, Märker-Hermann E.

Dtsch Med Wochenschr. 2006 Oct 13;131(41):2266-9. German.

PMID:
17036267
12.

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.

Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15.

13.

Nephroquiz 1: cyclophosphamide or mycofenolate mofetil?

Samadian F, Parvin M, Faraji A, Ahmadpoor P.

Iran J Kidney Dis. 2009 Apr;3(2):112-3. No abstract available.

14.

Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen.

Fujinaga S, Ohtomo Y, Hara S, Umino D, Someya T, Shimizu T, Kaneko K.

Pediatr Nephrol. 2008 Oct;23(10):1877-82. doi: 10.1007/s00467-008-0800-7. Epub 2008 Apr 15.

PMID:
18414900
15.

Determinants of patient survival in systemic lupus erythematosus--focusing on lupus nephritis.

Chan TM.

Ethn Dis. 2006 Spring;16(2 Suppl 2):S2-66-9. Review.

PMID:
16774014
16.

Ten common mistakes in the management of lupus nephritis.

Bose B, Silverman ED, Bargman JM.

Am J Kidney Dis. 2014 Apr;63(4):667-76. doi: 10.1053/j.ajkd.2013.10.056. Epub 2013 Dec 12. Review.

PMID:
24332767
17.

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.

Walsh M, Solomons N, Lisk L, Jayne DR.

Am J Kidney Dis. 2013 May;61(5):710-5. doi: 10.1053/j.ajkd.2012.11.042. Epub 2013 Feb 1.

PMID:
23375819
18.

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group..

Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

19.

Recent clinical trials in lupus nephritis.

Ward MM.

Rheum Dis Clin North Am. 2014 Aug;40(3):519-35, ix. doi: 10.1016/j.rdc.2014.05.001. Epub 2014 Jun 7. Review.

20.

Mycophenolate mofetil for treatment of refractory lupus nephritis: four pilot cases.

Wallman L, Stewart G, Chapman J, O'Connell P, Fulcher D.

Aust N Z J Med. 2000 Dec;30(6):712-5. No abstract available.

PMID:
11198579

Supplemental Content

Support Center